Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation.
Ariadna Montero-BlayJavier Delgado BlancoIrene Rodriguez-ArceClaire LastrucciCarlos Piñero-LambeaMaria LLuch-SenarLuis SerranoPublished in: Molecular systems biology (2023)
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that is active as a swapped domain dimer and is used in bacterial therapy of gut inflammation. IL-10 can be used as treatment of a wide range of pulmonary diseases. Here we have developed a non-pathogenic chassis (CV8) of the human lung bacterium Mycoplasma pneumoniae (MPN) to treat lung diseases. We find that IL-10 expression by MPN has a limited impact on the lung inflammatory response in mice. To solve these issues, we rationally designed a single-chain IL-10 (SC-IL10) with or without surface mutations, using our protein design software (ModelX and FoldX). As compared to the IL-10 WT, the designed SC-IL10 molecules increase the effective expression in MPN four-fold, and the activity in mouse and human cell lines between 10 and 60 times, depending on the cell line. The SC-IL10 molecules expressed in the mouse lung by CV8 in vivo have a powerful anti-inflammatory effect on Pseudomonas aeruginosa lung infection. This rational design strategy could be used to other molecules with immunomodulatory properties used in bacterial therapy.
Keyphrases
- pseudomonas aeruginosa
- poor prognosis
- inflammatory response
- oxidative stress
- stem cells
- type diabetes
- binding protein
- endothelial cells
- escherichia coli
- cystic fibrosis
- adipose tissue
- staphylococcus aureus
- small molecule
- skeletal muscle
- long non coding rna
- drug resistant
- cell therapy
- replacement therapy
- amino acid
- combination therapy
- biofilm formation
- toll like receptor